SEC Form PRER14A filed by Vaxart Inc
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/15/2024 | $4.00 | Outperform | Oppenheimer |
| 12/29/2021 | $13.00 → $12.00 | Buy | Jefferies |
| 11/2/2021 | $15.00 | Overweight | Cantor Fitzgerald |
| 6/30/2021 | $13.00 → $9.00 | Buy → Neutral | B. Riley Securities |
| 6/29/2021 | $13.00 → $9.00 | Buy → Neutral | B. Riley Securities |
| 6/24/2021 | $13.00 | Buy | Jefferies |
Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00
Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously
Cantor Fitzgerald initiated coverage of Vaxart with a rating of Overweight and set a new price target of $15.00
Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing Vaxart's Highly Qualified Directors with Candidates Who Have No Relevant Expertise Urges Shareholders to Vote "FOR" ALL Six of Vaxart's Director Nominees on the WHITE Proxy Card TODAY Visit Vote.Vaxart.com for Additional Information and Voting Resources SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platf
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit Vote.Vaxart.com for Additional Information SOUTH SAN FRANCISCO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that it has filed preliminary proxy materials with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 1
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second quarter of 2027 Live stockholder fireside chat scheduled for May 8, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced its business update and financial results for the first quarter of 2026. "In the first quarter of 2026, our team remained focused o
DEFA14A - Vaxart, Inc. (0000072444) (Filer)
DEFA14A - Vaxart, Inc. (0000072444) (Filer)
DEFA14A - Vaxart, Inc. (0000072444) (Filer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
Company is Entering a Pivotal Phase to Demonstrate Value of its Unique Oral Vaccine Platform Emphasizes Need for the Right Board Leadership at Critical Strategic Juncture Encourages Shareholders to Visit Vote.Vaxart.com for Additional Information SOUTH SAN FRANCISCO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that it has filed preliminary proxy materials with the Securities and Exchange Commission in connection with its upcoming Annual Meeting of Stockholders scheduled to be held on July 1
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second quarter of 2027 Live stockholder fireside chat scheduled for May 8, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced its business update and financial results for the first quarter of 2026. "In the first quarter of 2026, our team remained focused o
Appointment strengthens Board's clinical development and regulatory expertise as Vaxart advances its oral vaccine platform SOUTH SAN FRANCISCO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan. "We are pleased to welcome Jim to t
Company to report first quarter 2026 financial results on May 7 SOUTH SAN FRANCISCO, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) today announced that members of the Company's senior management team will participate in a virtual fireside chat on Friday, May 8, 2026 at 4:30 p.m. ET / 1:30 p.m. PT as part of its regular series to answer frequently asked questions from its stockholders. The Company plans to report financial results for the first quarter ended March 31, 2026, after the market close on Thursday, May 7, 2026. The live fireside chat can be accessed by clicking here or on the Company's website at www.vaxart.com. Investors may submit written questions in ad
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was safe and immunogenic in lactating women and resulted in passive transfer of antibodies to their infants via breast milk Cash, cash equivalents and investments of $63.8 million as of December 31, 2025; Runway into second quarter of 2027 Conference call today at 4:30 p.m. ET Live stockholder fireside chat scheduled for March 13, 2026 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX:VXRT) ("Vaxart" or the "Company"), a clin
Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will host two upcoming webcast conference calls. Full Year 2025 Business Update and Financial ResultsVaxart will provide a business update and report financial results for the full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. / 1:30 p.m. PT. The full year financial resul
SC 13G/A - Vaxart, Inc. (0000072444) (Subject)
SC 13G - Vaxart, Inc. (0000072444) (Subject)
SC 13G - Vaxart, Inc. (0000072444) (Subject)